Detalhe da pesquisa
1.
Thrombotic and bleeding complications in patients with AL amyloidosis.
Br J Haematol
; 204(5): 1816-1824, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38321638
2.
Small RNA-seq and clinical evaluation of tRNA-derived fragments in multiple myeloma: Loss of mitochondrial i-tRFHisGTG results in patients' poor treatment outcome.
Br J Haematol
; 204(5): 1790-1800, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38414235
3.
Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study.
Haematologica
; 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38356458
4.
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA.
Am J Hematol
; 99(3): 396-407, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38298023
5.
Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma.
Am J Hematol
; 2024 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38860642
6.
Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab-based therapy.
Br J Haematol
; 203(3): 411-415, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37580907
7.
miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma.
J Transl Med
; 21(1): 245, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37024879
8.
Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies.
Eur J Haematol
; 111(2): 271-278, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37218632
9.
Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma.
Int J Mol Sci
; 24(14)2023 Jul 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37511588
10.
miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome.
Br J Cancer
; 126(1): 79-90, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34718359
11.
Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine.
Br J Haematol
; 196(2): 356-359, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34528249
12.
Diabetes mellitus and multiple myeloma; common features of two distinct entities.
Diabetes Metab Res Rev
; 38(5): e3535, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35555946
13.
SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignancies.
Am J Hematol
; 97(10): 1300-1308, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35871310
14.
Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications.
Am J Hematol
; 97(9): 1142-1149, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35731917
15.
Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance.
Br J Haematol
; 193(1): 113-118, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32829529
16.
A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma.
Int J Mol Sci
; 22(23)2021 Dec 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34884950
17.
Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy.
Blood
; 139(9): 1409-1412, 2022 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34986251
18.
Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study.
Am J Hematol
; 99(3): 502-504, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38270219
19.
XBB.1.5 neutralizing antibodies upon bivalent COVID-19 vaccination are similar to XBB but lower than BQ.1.1.
Am J Hematol
; 98(5): E123-E126, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36810791
20.
Third dose of the BNT162b2 vaccine results in very high levels of neutralizing antibodies against SARS-CoV-2: Results of a prospective study in 150 health professionals in Greece.
Am J Hematol
; 97(4): E147-E150, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35025124